REMARKS

The parent application Serial No. 09/097,199 was filed on June 12, 1998. While this case was pending, divisional application Serial No. 09/662,270 was filed on September 14, 2000, and is still pending. Hence the present application is a co-pending application.

Claims 1-77 were originally filed in the parent case. In the present application, which is a second divisional application, claims 1-77 are cancelled and new claims 78-94 are added in this preliminary amendment. The new claims fall within the scope of Group IV as identified in the Restriction Requirement of September 17, 1999. A copy of the pending claims is included for the convenience of the examiner as Appendix A.

Support for the new claims may be found in specification at least on pg. 11, lines 6-8; pg. 18, lines 18-20; pg. 44, lines 24-27 and lines 8-12. Applicants submit that the new claims are supported in the original application and that no new matter is added.

The examiner is invited to contact the undersigned attorney at (512) 536-3081 with any questions, comments or suggestions relating to the referenced application.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45, 104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 10, 2001

Appendix A: Pending Claims

78. A method of treating a patient with cancer comprising administering to the patient an effective amount of an agent that inhibits a peptide or polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

79. The method of claim 78, wherein the agent is an antibody.

80. The method of claim 79, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

81. The method of claim 80, wherein the antibody is a monoclonal antibody.

82. The method of claim 80 wherein the antibody is a polyclonal antibody.

83. The method of claim 80, wherein the antibody is conjugated to a radionucleotide.

84. The method of claim 80, wherein the antibody is linked to a chemotherapeutic agent.

85. The method of claim 78, wherein the cancer is bladder cancer, breast cancer or prostate cancer.

86. The method of claim 78, wherein the agent inhibits SEQ ID NO: 3, SEQ ID NO: 83 or SEQ ID NO: 85 or a fragment thereof.

87. A method of treating a cancer cell comprising administering to the cell an effective amount of an agent that inhibits a peptide or polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85, or a fragment thereof.

88. The method of claim 87, wherein the agent is an antibody.

89. The method of claim 88, wherein the antibody is specific to a polypeptide encoded by SEQ ID NO:3, SEQ ID NO:83 or SEQ ID NO:85 or a fragment thereof.

90. The method of claim 88, wherein the antibody is a monoclonal antibody.

91. The method of claim 88, wherein the antibody is a polyclonal antibody.

92. The method of claim 88, wherein the antibody is conjugated to a radionucleotide.

93. The method of claim 88, wherein the antibody is linked to a chemotherapeutic agent.

94. The method of claim 87, wherein the cell is in a patient.--